Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. - Wikidata - wikimedia - TriplyDB

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

http://www.wikidata.org/entity/Q42678962

about

KASL clinical practice guidelines: management of chronic hepatitis B Efficacy of Tenofovir-Based Combination Therapy versus Tenofovir Monotherapy in Chronic Hepatitis B Patients Presenting with Suboptimal Responses to Pretreatment: A Meta-Analysis The Molecular and Structural Basis of HBV-resistance to Nucleos(t)ide Analogs Anti-HBV Drugs: Progress, Unmet Needs, and New Hope Current and future directions for treating hepatitis B virus infection Μanagement of patients with hepatitis B and C before and after liver and kidney transplantation Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments Outcome after discontinuation of nucleot(s)ide analogues in chronic hepatitis B: relapse rate and associated factors Direct acting antivirals for the treatment of chronic viral hepatitis Nucleoside/nucleotide analogues in the treatment of chronic hepatitis B Treatment strategies according to genotype for chronic hepatitis B in children Inhibitor-Based Therapeutics for Treatment of Viral Hepatitis Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis Cost-Effectiveness and Cost Thresholds of Generic and Brand Drugs in a National Chronic Hepatitis B Treatment Program in China Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Recent advances in micro/nanotechnologies for global control of hepatitis B infection Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women.Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load.Baseline HBsAg predicts response to pegylated interferon-α2b in HBeAg-positive chronic hepatitis B patients.Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir.A cutting-edge view on the current state of antiviral drug development.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.Hepatitis B-associated fibrosis and fibrosis/cirrhosis regression with nucleoside and nucleotide analogs.Strategies to eliminate HBV infection.Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.AASLD guidelines for treatment of chronic hepatitis B.Quantitative HBsAg and HBeAg predict hepatitis B seroconversion after initiation of HAART in HIV-HBV coinfected individuals.Clinical Relevance of Minimal Residual Viremia during Long-Term Therapy with Nucleos(t)ide Analogues in Patients with Chronic Hepatitis B.Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.Tenofovir monotherapy versus tenofovir plus lamivudine or telbivudine combination therapy in treatment of lamivudine-resistant chronic hepatitis B Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.Comparison of the efficacy of tenofovir disoproxil fumarate and entecavir for initial treatment of patient with chronic hepatitis B in China.Antiviral therapies and prospects for a cure of chronic hepatitis B.Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years Current Antiviral Therapy of Chronic Hepatitis B: Efficacy and Safety Hepatitis B virus genotypes and variants.Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.Virologic response and safety of tenofovir versus entecavir in treatment-naïve chronic Hepatitis B patients

P2860

Q26752475-DC040523-2E24-49BE-9E24-963E7B660052 Q26765932-EFA3E254-9CF7-42A7-AA18-300F38A16C6B Q26781795-E95FFAEB-44A0-451F-A4AD-5C2F5F71BA9A Q26782742-E08DEF62-8769-4C01-A2CF-99F985A71B13 Q26851240-D63368FB-637B-4E42-A240-F95193488968 Q26864647-336E787F-8D36-418A-A1EA-2706B0EBC0D7 Q27008984-A33E4A9D-646E-4D9D-87D3-14882FFF158A Q27020938-B6DB5992-4A32-41F8-A82D-73B9D6406EA3 Q27022216-D421CD14-11FB-48DD-BD32-D16FB4B31E53 Q27030828-C771D403-96BC-4F0C-8D5F-FC2D8DC30429 Q28066476-6F6F243A-0F30-44F5-B683-406A4DA1B64C Q28073697-AADFF54B-8C28-4633-A019-FCCBAFDB00A1 Q28468387-8AF25292-DD69-4DC4-9E94-D52F1E5276BE Q28539472-52788E57-AB04-4D9A-BA7B-BF6B293D5E31 Q28550643-B780FBC4-B84F-428B-9DDC-7F72E5A7842C Q30391932-E8DC15C6-23F9-4D63-9100-EC6DDD8826C5 Q30394611-274637DF-CC7F-4090-A5B2-1B76393CCA25 Q30860824-779BC233-9DCD-43EE-BDF3-F27748A575FF Q33711399-75998D63-870E-46E2-8AE5-2D6D53B89538 Q33829957-FBCA4BF0-A4E8-4719-9D3C-82730E8F5FBE Q33845546-7608BFA1-3273-467B-9F46-87B6A74D78F5 Q33857643-07A6A2D4-5B88-4A50-9AF0-98E66BCC4B69 Q34036018-906A82B6-6A81-4C01-A12E-A83614343D74 Q34137291-DE2E3D84-35B2-4EF3-8DF4-7C8B6F7895B6 Q34257596-0CE58445-508C-43F2-B333-A427A0C7F774 Q34308129-8B48059F-6576-4932-9D42-C29C56388C7C Q34384793-A3A48F0F-474A-4642-B23A-2B07A5D82DB6 Q34501660-3062770A-40AD-46E4-917B-2DC72D686E93 Q34674838-E2933496-E0CD-42BA-A56B-BB89CB037B99 Q34797281-485B6E37-236B-45FC-8E52-06E8785160A1 Q34948124-328B6057-4BFC-44C4-94A8-68682F7BAA80 Q35105892-75445BDF-32E8-453B-853D-68E12E59E9D8 Q35152367-7A7F46E8-DD57-400C-9B45-BCAEA480E800 Q35173563-408610B5-D66A-4925-A901-F5756D6D7CD9 Q35245231-659376AC-77CA-4FAF-8AA7-7A75424B7A20 Q35288973-680595DF-7986-48DC-88BC-54775A5669A6 Q35535861-1E1A900A-3762-444F-A534-E5EA5D08205B Q35663838-334E31E3-89FB-4D71-9625-4D9693FCCD42 Q35671645-B51E67E5-E679-48E8-BA2E-4BCEA97450E7 Q35681979-44A74801-3C96-4B11-A7FE-8B81E7682291

P2860

Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.

http://www.wikidata.org/entity/Q42678962

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@en

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@nl

type

label

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@en

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@nl

prefLabel

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@en

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@nl

P1433

Q42678962-C88B0173-2893-40C1-A8BC-C6D763017D13

P1476

Q42678962-E7F33B75-EA28-4D31-8119-C7BD90C3948E

P2093

Q42678962-0E9B3B34-0469-4D5C-8FDF-0302F01815F8

Q42678962-1077A478-63F6-4431-97BE-EEA4EB08856E

Q42678962-19FBCEDB-AB54-48E1-A58F-BB8F9D86DE5D

Q42678962-207E5057-F5D1-4289-85A2-E50764988EE2

Q42678962-2FE1DBA6-F010-4278-81EE-F42BCA60C2D0

Q42678962-3047C8BD-89DF-4401-A7E5-C8179221CFD2

Q42678962-3DBC7C1B-00D2-40F9-A0AA-CE93F9D060F9

Q42678962-44722020-3291-43BD-B623-76429DC2EFE7

Q42678962-667162B2-0374-4B7E-9B54-D60E5CD269E4

Q42678962-6BE6DA6A-1620-4BA9-A8FB-89D2C7550EC6

P304

Q42678962-6CC97502-0B2D-434D-BB26-088C35D108E7

P31

Q42678962-B8049852-8D7B-4BBF-B84A-34EBA926CA74

P356

Q42678962-083BF6E9-E4A8-47A3-8612-4AE861894C1A

P407

Q42678962-D8ED2D61-AE94-4A63-88A4-FC5849FF2B22

P433

Q42678962-080DC943-875F-455C-BA6B-4048655F72E7

P478

Q42678962-64BD0054-A7DE-45F7-BA88-82F4541E43DC

P50

Q42678962-9F897622-0CBB-44D9-8ACA-F282F5591BD8

Q42678962-EABB5FCF-C20D-4E73-8469-D3A4811D1331

P577

Q42678962-F5A8E9DA-CEF3-4E52-B81F-CDC40D356E42

P5875

Q42678962-BC5709D4-FFC8-4243-8F14-875616D8BA2C

P698

Q42678962-267399D0-2E93-4252-B13E-09AD361D412E

P356

J.GASTRO.2010.10.011

P1433

Gastroenterology

P1476

Three-year efficacy and safety ...... tment for chronic hepatitis B.

@en

P2093

Andrea Snow-Lampart

http://www.w3.org/2001/XMLSchema#string

E Jenny Heathcote

http://www.w3.org/2001/XMLSchema#string

Edward Gane

http://www.w3.org/2001/XMLSchema#string

Elsa Mondou

http://www.w3.org/2001/XMLSchema#string

Franck Rousseau

http://www.w3.org/2001/XMLSchema#string

Frank Weilert

http://www.w3.org/2001/XMLSchema#string

George Germanidis

http://www.w3.org/2001/XMLSchema#string

Huy Trinh

http://www.w3.org/2001/XMLSchema#string

Iskren Kotzev

http://www.w3.org/2001/XMLSchema#string

Jane Anderson

http://www.w3.org/2001/XMLSchema#string

P304

132-143

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1053/J.GASTRO.2010.10.011

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

140

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-10-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

47458706

http://www.w3.org/2001/XMLSchema#string

P698

20955704

http://www.w3.org/2001/XMLSchema#string